Skip to content
Markets

Biocon wins EU approval for breast cancer biosimilar Pebrilzo

The European authorization clears a regulatory hurdle for Biocon’s version of pertuzumab. A patent settlement sets out an earlier launch window for Europe than for the United States.

By Alex Morgan2 min read

Alex Morgan is an editorial pen name used for AI-assisted news summaries by tailorinvests.com.

Illustration of two unbranded medicine vials with faint antibody shapes in the background.
AI-generated editorial illustration

Indian drugmaker Biocon said on November 18 that the European Commission had granted marketing authorization for Pebrilzo, its version of the breast cancer medicine pertuzumab. Biocon disclosed the decision to Indian stock exchanges that morning, and Upstox reported it by 9:10 a.m. in India (03:40 UTC). The authorization covers certain uses in adults with HER2-positive breast cancer.

The decision clears a regulatory hurdle in the European Union. The timeline for sales also depends on a separate patent settlement. Biocon said in October that its agreement with Genentech allows a launch in the EU and the United Kingdom from the first quarter of 2027 and in the United States from the third quarter of 2028, with earlier entry possible in certain circumstances.

Why the evidence review matters

A biosimilar is a biological medicine shown to be highly similar to an already authorized medicine. For Pebrilzo, the reference product is Perjeta. The European Medicines Agency’s expert committee recommended Pebrilzo in September and identified it as the first biosimilar to receive a positive recommendation through its tailored clinical approach.

The approach can let developers rely more on detailed laboratory comparisons and studies of how the medicine behaves in the body. For some well-characterized products, the agency says a separate trial comparing clinical effectiveness may be unnecessary when the other evidence is sufficiently informative. That can change which studies a company budgets for, though it still has to demonstrate biosimilarity.

Authorization and sales have different timelines

Biocon has now reported regulatory clearance in both the EU and the U.S., but the agreed launch windows differ by more than a year. The European decision applies to the EU; mentioning the UK in the patent agreement does not extend that authorization to the UK.

For investors assessing potential sales, the next useful details are the actual launch date, the price and how widely the product is adopted. The November announcement establishes that Biocon can move forward in the EU. It does not establish how quickly hospitals will buy the drug or what it will contribute to earnings.

Go to the source

For general education. Consider your circumstances and local rules before making investment decisions. Figures describe the dates stated in this article and are not live market quotes.

Build your investing knowledge